Literature DB >> 11278481

Pdx-1 is required for activation in vivo from a duodenum-specific enhancer.

M R Dusing1, E A Florence, D A Wiginton.   

Abstract

The purine metabolic gene adenosine deaminase (ADA) is expressed along a defined spatiotemporal pattern in the developing mammalian small intestine, where high-level expression is limited to the villous epithelium of the duodenum. This activation is observed in rodents as the intestine completes the final maturation resulting in adult crypt-villus structures at 2-3 weeks postpartum. A regulatory module responsible for this pattern of expression has been identified in the second intron of the human ADA gene. Of the multiple duodenal proteins that can interact with this small duodenal enhancer region, the studies contained in this work describe the identification of five of these proteins as the dispersed homeobox protein PDX-1. This transcription factor exhibits a profile of expression in the small intestine similar to that observed for ADA, making it an ideal candidate factor for the duodenum-specific ADA enhancer. Loss of PDX-1 binding, via a PDX-1 mutated enhancer transgenic construction, resulted in complete loss of high-level activation in the duodenum, demonstrating the absolute requirement for this factor in vivo. However, co-transfection experiments suggest that other proteins that bind the enhancer are also required for enhancer function because PDX-1 alone was incapable of significant transactivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278481     DOI: 10.1074/jbc.M009249200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Intron 1 is required for cell type-specific, but not injury-responsive, peripherin gene expression.

Authors:  Thomas E Uveges; Yuqing Shan; Bridget E Kramer; David C Wight; Linda M Parysek
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

2.  PDX1 regulation of FABP1 and novel target genes in human intestinal epithelial Caco-2 cells.

Authors:  Chin Chen; Rixun Fang; Lin-Chiang Chou; Anson W Lowe; Eric Sibley
Journal:  Biochem Biophys Res Commun       Date:  2012-05-26       Impact factor: 3.575

3.  Direct transcriptional regulation of Gata4 during early endoderm specification is controlled by FoxA2 binding to an intronic enhancer.

Authors:  Anabel Rojas; William Schachterle; Shan-Mei Xu; Franz Martín; Brian L Black
Journal:  Dev Biol       Date:  2010-08-06       Impact factor: 3.582

4.  Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development.

Authors:  Jean-Sébastien Annicotte; Elisabeth Fayard; Galvin H Swift; Lars Selander; Helena Edlund; Toshiya Tanaka; Tatsuhiko Kodama; Kristina Schoonjans; Johan Auwerx
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

5.  An endoderm-specific transcriptional enhancer from the mouse Gata4 gene requires GATA and homeodomain protein-binding sites for function in vivo.

Authors:  Anabel Rojas; William Schachterle; Shan-Mei Xu; Brian L Black
Journal:  Dev Dyn       Date:  2009-10       Impact factor: 3.780

6.  GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage.

Authors:  Lisa I Jepeal; Michael O Boylan; M Michael Wolfe
Journal:  Mol Cell Endocrinol       Date:  2008-02-08       Impact factor: 4.102

7.  Pdx1 inactivation restricted to the intestinal epithelium in mice alters duodenal gene expression in enterocytes and enteroendocrine cells.

Authors:  Chin Chen; Rixun Fang; Corrine Davis; Charalambos Maravelias; Eric Sibley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-01       Impact factor: 4.052

8.  In vitro patterning of pluripotent stem cell-derived intestine recapitulates in vivo human development.

Authors:  Yu-Hwai Tsai; Roy Nattiv; Priya H Dedhia; Melinda S Nagy; Alana M Chin; Matthew Thomson; Ophir D Klein; Jason R Spence
Journal:  Development       Date:  2016-12-07       Impact factor: 6.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.